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Background: Cancer pharmacogenetic studies use archival tumor samples as a DNA source
when germline DNA is unavailable. Genotyping DNA from formalin-fixed paraffin
embedded tumors (FFPE-T) may be inaccurate due to FFPE storage, genetic aberrations,
and/or insufficient DNA extraction. Our objective was to assess the extent and source of
genotyping inaccuracy from FFPE-T DNA and demonstrate analytical validity of FFPE-T
genotyping of candidate single nucleotide polymorphisms (SNPs) for pharmacogenetic
analyses.
Methods: Cancer pharmacogenetics SNPs were genotyped by Sequenom MassARRAYs in
DNA harvested from matched FFPE-T, FFPE lymph node (FFPE-LN), and whole blood leuko-
cyte samples obtained from breast cancer patients. No- and discordant-call rates were
calculated for each tissue type and SNP. Analytical validity was defined as any SNP with
<5% discordance between FFPE-T and blood and <10% discordance plus no-calls.
Results:Matched samples from 114 patients were genotyped for 247 SNPs. No-call rate in
FFPE-T was greater than FFPE-LN and blood (4.3% vs. 3.0% vs. 0.5%, p < 0.001). Discor-
dant-call rate between FFPE-T and blood was very low, but greater than that between
FFPE-LN and blood (1.1% vs. 0.3%, p < 0.001). Samples with heterozygous genotypes weren embedded; FFPE-T, Formalin-fixed paraffin embedded tumor; FFPE-LN, formalin-fixed
gle nucleotide polymorphism; MAF, minor allele frequency; HWE, HardyeWeinberg
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M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 8 6 8e1 8 7 6 1869more likely to be no- or discordantly-called in either tissue (p < 0.001). Analytical validity of
FFPE-T genotyping was demonstrated for 218 (88%) SNPs.
Conclusions: No- and discordant-call rates were below concerning thresholds, confirming
that most SNPs can be accurately genotyped from FFPE-T on our Sequenom platform.
FFPE-T is a viable DNA source for prospectiveeretrospective pharmacogenetic analyses
of clinical trial cohorts.
ª 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
reserved.1. Introduction perhaps due to isolated reports of inadequate genotyping per-In cancer there are two relevant genomes, that of the tumor
(somatic) and the patient (germline) (McLeod, 2013). The so-
matic genome has been the area of intense basic and clinical-
translational research. Analyses of the somatic genome across
tumor types have cataloged oncogenic drivers, many of which
are now targets for precision medicine (Kandoth et al., 2013).
The germline genomemay be less directly involved in predict-
ing cancer treatment effectiveness compared to tumordenovo
and acquired resistance mechanisms, but highly relevant for
predicting cancer susceptibility and drug exposure, which
can have critical downstream effects on treatment efficacy
and toxicity (Hertz and McLeod, 2013; Hertz and Rae, 2015).
There is great interest in discovering pharmacogenetic predic-
tors for personalizing cancer therapy. In order to do so, DNA
from cohorts of patients with long-term clinical outcomes
data are required for definitive “prospectiveeretrospective”
pharmacogenetic analyses (Patterson et al., 2011).
Since tumor assessment is ubiquitous in cancer treatment,
there are hundreds of thousands of stored specimens avail-
able for retrospective biomarker research. The ability to use
the DNA extracted from these tumors, particularly those
formalin-fixed paraffin embedded (FFPE), for germline genetic
association testing would dramatically increase the availabil-
ity of cohorts for prospectiveeretrospective studies. However,
germline genotyping requires demonstration of analytic valid-
ity; that the results obtained from genotyping DNA isolated
from FFPE tumors (FFPE-T) are concordant with those ob-
tained from genotyping germline DNA. There is concern that
analytic validity may be compromised due to somatic genetic
alteration, DNA degradation during FFPE processing and stor-
age, and/or low DNA yield during extraction from stored tu-
mor specimens.
Previous publications have assessed genotype concordance
between germline DNA and DNA isolated from tissues stored
in a variety of conditions (Supplementary Table 1). Very high
genotyping concordance (>97%) has been documented
comparing germline DNA and with DNA isolated from FFPE
non-tumor tissue (Adank et al., 2006; Cannon-Albright et al.,
2011; Hagleitner et al., 2011; Vos et al., 2015; Xie et al., 2006;
Zhang et al., 2015), non-FFPE tumor tissue (Marsh et al., 2005;
A. Thompson et al., 2010) and FFPE-T tissue (Goetz et al.,
2005; Horn et al., 2010; Rae et al., 2003, 2013; van Huis-Tanja
et al., 2013). Despite thesehighly consistent findings there con-
tinues to be concern raised regarding the use of FFPE-T DNA in
retrospectiveeprospective studies (Nakamura et al., 2012),formance for single SNPs genotyped from FFPE-T (Goetz et al.,
2014; Marisi et al., 2014). Given these concerns, it is critical to
demonstrate analytic validity of genotyping FFPE-T prior to
prospectiveeretrospective analyses (Greytak et al., 2015). We
collected matched FFPE-T, FFPE non-cancer lymph node
(FFPE-LN), and germline DNA to document high genotyping
concordance in CYP2D6, which we previously reported (Rae
et al., 2013). In this study we reused these samples to assess
the overall genotyping performance from FFPE-T and docu-
ment analytic validity of genotyping our target SNPs pertinent
to cancer pharmacogenetics on a custom multiplex array in
FFPE-T DNA for prospectiveeretrospective analyses.2. Methods
2.1. Patient enrollment and sample collection and
processing
Details of patient recruitment and enrollment, sample collec-
tion and processing, and DNA preparation have been previ-
ously published (Rae et al., 2013). Briefly, patients seen
consecutively by their University of Michigan breast medical
oncology team were offered the opportunity to participate in
this study, ClinicalTrial.gov identifier NCT00858585. Eligible
patients were over the age of 21, carried the diagnosis of inva-
sive breast cancer and were able to provide access to FFPE
archived primary tumor and benign lymph node tissues. Pa-
tients who received neo-adjuvant chemotherapy were eligible
but patients with metastatic disease were not.
An 8 mL whole blood sample was collected in a 10 mL
EDTA vacutainer tube for germline DNA isolation from pe-
ripheral leukocytes. Whole blood was stored on ice or at
4 C. Whole blood was aliquoted within 8 h of collection
into one 0.5 mL sample and the remainder into 1 mL aliquots,
which were stored at 80 C. Stored FFPE tumor blocks were
obtained from the University of Michigan Pathology Depart-
ment and stored at room temperature until processing.
DNA was extracted from peripheral whole blood samples
within 24 h of collection using the Qiagen DNeasy Blood
and Tissue Kit (kit 69506, Valencia, California, USA) and
from FFPE-T and unaffected FFPE-LN utilizing the same kit
in conjunction with a previously published protocol (Sikora
et al., 2011). The amount of useable DNA was quantified in
the samples via Nanodrop. DNA was stored at 80 C until
genotyping was performed.
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Approximately 30 mL of DNA from whole blood, FFPE-T and
FFPE-LN was submitted to the University of Michigan DNA
Sequencing core. Assayswere designed using standard Seque-
nom software (both online Assay Design Suite tools and
desktop Assay Design 4.0) and assays were performed using
a Sequenom MassARRAY Compact instrument, according to
manufacturer’s standard protocols. Results were processed
to generate SNP calls automatically, using Sequenom TyperA-
nalyzer software, and thenmanually reviewed by the operator
to validate the allele calls. Automatic SNP calls that were of
concern, based on questionable spectra, were removed. A to-
tal of 304 unique SNPs were genotyped on 8 Sequenom Mas-
sARRAY plexes with up to 40 SNPs each. These SNPs were
not selected specifically for this project, but represent a collec-
tion of candidate SNPs relevant to the metabolism, mecha-
nism, or toxicity of breast cancer treatments, for genotyping
in prospectiveeretrospective pharmacogenetic analyses of
breast cancer clinical trials. Sample concentration was deter-
mined using a Nanodrop spectrophotometer. Ideal sample
concentrations for Sequenom are between 50 and 100 ng/ml.
DNA concentrations were less than optimal from FFPE-T
(median ¼ 10.09, range: 0.78e88.0) and FFPE-LN
(median ¼ 57.00, range 2.57e97.29).2.3. Sample and SNP quality control
Sampleswithwholebloodcall rate<95%or tumorcall rate<80%
were eliminated prior to analysis. SNPs were eliminated for
blood sample genotype call rate <95%, minor allele frequencyFigure 1 e Consort Diagram for Patients and SNPs. Quality control filterin
and SNPs that failed genotyping in blood (right). After quality control 114
genotyped for 247 independent SNPs were included in the analysis. Footn
HardyeWeinberg Equilibrium.<2%, or if the p-value for HardyeWeinberg Equilibrium (HWE)
was<0.0002 (0.05/304), to remove weak or failed SNP assays.2.4. Genotyping performance within sample types
Patients with all three matched tissue types (blood, FFPE-T,
and FFPE-LN) that passed quality control were included in
the analysis. Genotyping performance in each tissue type
was compared in several ways. The overall no-call rate was
calculated for all three tissue types. The no-call rates in
FFPE-T and FFPE-LN were also calculated by genotype (hetero-
zygous or homozygous), assuming the genotype call in blood
was correct. Discordance was defined in two ways: strict
discordance and possible discordance. Strict discordance is a
different genotype call made in the tissue of interest (FFPE-T
or FFPE-LN) compared with blood. Possible discordance com-
bines strict discordance and instances in which a genotype
call was not made in either blood or the tissue of interest
(FFPE-T or FFPE-LN). Strict and possible discordance rates
overall were calculated similarly to no-call rates. Strict discor-
dance rates were also calculated by genotype, and each
discordant instancewas categorized into the 3 possible transi-
tions between homozygous and heterozygous, again
assuming the blood genotype call was correct.2.5. Analytical validation of SNPs
FFPE-T genotyping results for individual SNPs were interro-
gated to identify SNPs with unacceptable rates of no-calls
and/or discordant calls. SNPs failed analytical validation if
they had FFPE-T strict discordance rate >5% or possibleg of patients whose samples failed genotyping in blood or tumor (left)
patients with matched blood, FFPE-T and FFPE-LN samples
ote: Abbreviations: MAF: Minor allele frequency, HWE:
Figure 2 e Genotyping for FFPE-T. Concordance between FFPE-T and blood for all patients (n[ 114) and SNPs (n[ 247) that passed quality
control. (A) Discordant calls (blue) and no-calls in either the tumor (light blue) or blood (white) are represented by colors. (B) The number of possible
discordant calls (strict discordant calls plus no-calls in tumor or blood) for all SNPs with stacked bars colored similarly to Figure 1A. The horizontal
lines indicate cutoffs of 5%, 10%, and 20%. Overall, the tumor genotyping was highly concordant with few SNPs that failed FFPE-T genotyping.








No calls Overalla 0.5%
(135/28158)
4.3% (1221/28158) <0.001 3.0% (843/28158) <0.001 <0.001
By genotypeb Homozygous NA 1.8% (346/18900) <0.001 2.5% (468/18900) <0.001 NA




Overalld NA 1.1% (306/26813) NA 0.3% (84/27192) NA <0.001
By genotypee Homozygous NA 0.2% (33/18554) <0.001 0.2% (32/18432) <0.001 NA
Heterozygous NA 3.3% (273/8259) 0.6% (52/8760)
Direction of
discordancef
Hom/ Het NA 10.8% (33/306) NA 28.6% (24/84) NA NA
Het/ Hom NA 89.2% (273/306) 61.9% (52/84)




Overallh NA 5.9% (1651/28158) NA 3.7% (1050/28158) NA <0.001
Abbreviations: Het ¼ Heterozygous genotype call, Hom ¼ Homozygous genotype call.
a Overall no-call rate calculated by: # no-calls/28158 genotype calls (247 SNPs in 114 patients).
b No-call rate by genotype calculated by: # no-calls/# calls of that genotype. Note this excludes 135 SNPs with no-calls in blood.
c Strict discordance defined as a genotype call was made in both blood and FFPE-T (or FFPE-LN) and the calls were different.
d Overall strict discordant call rate calculated by: # genotype calls in FFPE-T (or FFPE-LN) that are different from genotype call in blood/# of ge-
notype calls in FFPE-T (or FFPE-LN) and blood. Note that any sample with a no-call in FFPE-T (or FFPE-LN) or blood excluded from calculation.
e Strict discordance rate by genotype calculated by: # genotype calls in FFPE-T (or FFPE-LN) that are different from genotype call in blood/# of
genotype calls in FFPE-T (or FFPE-LN) and blood of that genotype. Note that any sample with a no-call in FFPE-T (or FFPE-LN) or blood excluded
form calculation.
f Type of discordance with the genotype call in blood first and the genotype call in the tissue of interest second. Percentage calculated as the # of
discordant calls in that direction/the number of total discordant calls.
g Possible discordance defined as either a strict discordant call was made or a genotype call was not made in blood or FFPE-T (or FFPE-LN).
h Overall possible discordance calculated by: # of genotype calls in FFPE-T (or FFPE-LN) that are different from genotype calls in blood plus num-
ber of no-calls in FFPE-T (or FFPE-LN) or blood/28158 genotype calls (247 SNPs in 114 patients).
i P-values compare FFPE-T or FFPE-LN vs. blood, FFPE-T vs. FFPE-LN, or homozygous vs. heterozygous within sample type, as appropriate.
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considered analytically validated.2.6. Statistical methods
Comparisons of call rates (no-calls, strict discordant calls,
possible discordant calls) between tissue types (blood, FFPE-
T, FFPE-LN) were analyzed using mixed effects logistic regres-
sion with random effects for subjects and SNPs and primary
covariate of interest being tissue type. Similar models were
used for differences by genotype with the covariate of interest
being the interaction between genotype and tissue type.
Spearman Correlation was used to measure the association
between no-call or discordant call rate and DNA concentra-
tion. All statistical analyses were performed using SAS v9.3.3. Results
3.1. Sample quality control
Flow diagrams that describe the filtering of patients and SNPs
are displayed in Figure 1. After exclusion of four patients’ sam-
ples due to unacceptable genotype call rates in blood (<95%,
n¼ 1) or FFPE-T (<80%, n¼ 3), 114 patients withmatched sam-
ples were included in the analysis. There was a statisticallysignificant correlation between FFPE-T DNA concentration
and call rate (r ¼ 0.48, p < 0.0001, Supplementary Figure 1).
Quality control was then performed on the 304 individual
SNPs, with 247 passing all quality control metrics. These 247
SNPs were ordered by chromosomal location and assigned la-
bels that indicate the chromosome (#) and their position (let-
ter) (Supplementary Table 2). The eliminated SNPs (n ¼ 57,
See Supplementary Table 3) failed due to low call rate
(<95%, n ¼ 24), low minor allele frequency (MAF) (<2%,
n ¼ 31), or significant deviation from HWE (p < 0.0002, n ¼ 2)
in blood sample genotyping.3.2. Genotyping performance by tissue and sample
Concordant, discordant, and no-calls in FFPE-T for all patients
and SNPs, and the summary rate of discordance per SNP, are
displayed in Figure 2A and B, respectively. The summary no-
call and discordant call rates in all three tissue types are re-
ported in Table 1. Across the 28,158 genotype calls in the 247
SNPs among 114 patients the overall no-call rates were higher
in the FFPE-T (4.3%) than FFPE-LN (3.0%), and higher in either
compared to blood (0.5%) (p < 0.001 for all comparisons)
(Supplementary Figure 2). The pattern was similar for strict
discordant calls, with the strict discordance rate being greater
in FFPE-T than FFPE-LN (1.1% vs. 0.3%, p < 0.001). Assuming
the blood genotype is correct, heterozygous samples were
Table 2 e SNPs with strict discordance>5% in FFPE-T.
Study label Gene rsID Strict discordance
(# FFPE-T discordant/
# genotype calls in blood
and tumor)
6AI ESR1 rs2347869 6% (7/110)
11B PGR rs500760 6% (6/108)
15E CYP19A1 rs9806371 12% (11/90)
22E COMT rs4633 7% (8/108)
M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 8 6 8e1 8 7 6 1873significantly more likely than homozygous samples to have
no-calls or strict discordant calls in both FFPE-T and FFPE-LN
(p < 0.001 for all comparisons). Of the strict discordant calls,
the majority was heterozygous samples incorrectly called ho-
mozygous (FFPE-T: 89.2% of 306 discordant calls, FFPE-LN:
61.9% of 84 discordant calls).
When assessed by patient sample sets across 247 SNPs the
discordance was not randomly distributed. The majority of
FFPE-T samples had no strict discordant calls (64/
114 ¼ 56.1%), while 6 (4.2%) had strict discordance rates
>5%. There was a weak, but statistically significant inverse
correlation between FFPE-T DNA concentration and strict
discordance (r ¼ 0.20, p ¼ 0.031, Supplementary Figure 3).
3.3. Analytical validation of SNPs
Looking within each SNP across all 114 samples, 29 unique
SNPs failed at least one performance metric in FFPE-T geno-
typing. Four SNPs (4/247 ¼ 1.6%) had a strict discordance
rate >5% (Table 2, Figure 3), 28 (11.3%) SNPs had a possible
discordance rate >10% (Table 3), and 3 SNPs failed both met-
rics. Overall 88.3% (218/247) of the SNPs were analytically vali-
dated (Supplementary Figure 4).Figure 3 e Strict discordance rates for FFPE-T and FFPE-LN.
Histogram of the strict discordance rates in FFPE-T and FFPE-LN,
each comparedwith blood, for all SNPs included in the analysis.Overall
the discordance rates were quite low, with very few SNPs having more
than 1% discordant calls between either tissue of interest and blood.4. Discussion
In this study,we assessed the genotyping performance inDNA
extracted from FFPE-T samples for 247 cancer pharmacoge-
netic SNPs genotyped on a custom Sequenom panel. Overall
we found adequate call rates (95.7%) and very strong concor-
dance (98.9%) to germline genotyping, consistent with previ-
ous publications (Goetz et al., 2005; Horn et al., 2010; Rae
et al., 2003, 2013; van Huis-Tanja et al., 2013), reaffirming the
analytic validity of genotyping stored tumor specimens for
prospectiveeretrospective secondary analyses of clinical
trials. The no-call rate in FFPE-T (4.3%) is below typical thresh-
olds used for quality control in pharmacogenetic analyses
(<5%) and the extremely low rate of strict discordant calls
(1.1%) is well below reasonable thresholds of concern for
correlative pharmacogenetic research. Analytic validity was
demonstrated for genotyping 218 unique candidate SNPs on
our custom platform from DNA extracted from FFPE-T.
There are several theoretical concerns with genotyping
FFPE-T DNA. The first is the degradation of DNA from formalin
fixation and long-term storage. Assessment of matched FFPE-
LN enables us to isolate the contribution of FFPE processing
and storage to the genotyping error seen in this study. The
no-call rate in FFPE-LN was approximately 70% of that of
FFPE-T, suggesting that most of the non-calling in FFPE-T is
attributable to the FFPE process, consistent with what we re-
ported previously for matched CYP2D6 genotyping (Rae
et al., 2013). The extremely low rate of discordance in FFPE-
LN (0.3%) is in line with discordance rates from comparisons
of germline and FFPE non-tumor tissue (0%e2.6%) (Adank
et al., 2006; Cannon-Albright et al., 2011; Hagleitner et al.,
2011; Vos et al., 2015; Xie et al., 2006; Zhang et al., 2015) and
similar to the 3% discordance reported in a comparison of
matched fresh frozen and FFPE ovarian tumors genotyped
on a genome-wide genotyping array (E. R. Thompson et al.,2005). In a secondary analysis we identified a slight increase
in FFPE-T strict discordance rate as the amount of time in
FFPE storage increased (spearman correlation r ¼ 0.22,
p ¼ 0.017), which is consistent with an increasing loss of
DNA quality reported by others (Hedegaard et al., 2014). These
findings clearly demonstrate that the FFPE processing and
long-term storage have a small, but real, effect on genotyping
performance.
Somatic genetic aberrations, including LOH, are the sec-
ond potential concern with FFPE-T genotyping. The strict
discordance in FFPE-LN only accounted for 27.2% of that
seen in FFPE-T, suggesting that the tumor genome may intro-
duce some genotyping errors, as has been documented by
some groups for individual SNPs (Goetz et al., 2014; Marisi
et al., 2014). It is even possible that the discordance seen in
a given patient could depend on the section of tumor from
which the DNA was extracted due to intra-tumor heterogene-
ity. Alternatively, several other groups have reported high
concordance (>98.9%) between comparisons of germline
and frozen (non-FFPE) tumor (Marsh et al., 2005; A.
Thompson et al., 2010) and matched FFPE normal and malig-
nant tissue (Ahern et al., 2010; Schneider et al., 2006). This
high concordance in direct comparisons of tumor versus
normal that were similarly processed and stored confirms
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ror. The enrichment of discordance within heterozygous
samples could be taken as evidence that tumor LOH inter-
feres with genotyping accuracy a small amount, however,
LOH is not the only, or even the most likely, explanation for
this enrichment. The Sequenom MassARRAY calls genotypes
by signal detection from each allele; therefore, accurate geno-
type calling of heterozygous samples can be more chal-
lenging, particularly for assays with differential binding
efficiencies. This alternative hypothesis is supported by the
coincident enrichment in heterozygous samples for no-
calls, which would not be a consequence of LOH, and strict
discordant calls in heterozygous FFPE-LN samples, which do
not contain LOH.
The final concern with FFPE-T genotyping is the compara-
tively low yield of DNA extracted from these samples. We
found that no-call and discordant call rates were higher in
FFPE-T with lower DNA concentration. DNA extraction yield
can vary greatly depending on the tumor sample type (i.e.
core biopsy or section), size, and tumor content and genotyp-
ing platforms vary in their minimal DNA requirement and
sensitivity to low DNA concentration. Thus, ensuring
adequate sample availability, maximizing DNA extraction,
and using genotyping platforms that are less sensitive to the
amount of DNA template could further improve genotyping
performance from FFPE-T.Table 3 e SNPs with possible discordance>10% in FFPE-T.
Study label Gene rsID # FFPE-T strict
discordant calls
# F
4E VEGFC rs1485766 1
6O ESR1 rs2046210 5
6T ESR1 rs3853250 3
6Z ESR1 rs1709181 4
6BD OPRM1 rs1799971 1
7A Intergenic rs2097903 2
7F ABCB1 rs2032582 2
7G CYP3A rs10273424 0
9A SLC28A3 rs7853758 0
10M CYP2C8 rs11188172 0
10Q CYP17A1 rs4919687 0
11Bb PGR rs500760 6
12M NCOR2 rs1812730 1
13J HTR2A rs6311 2
13L SLC10A2 rs2301159 3
14I ESR2 rs1952585 1
14R AKT1 rs2494732 3
15Eb CYP19A1 rs9806371 11
15S CYP19A1 rs730154 0
15U CYP19A1 rs4774585 2
16D SPG7 rs12960 4
17A PELP1 rs9436 2
22D COMT rs6269 1
22Eb COMT rs4633 8
22F COMT rs4818 3
22L EP300 rs20551 1
22Q NDUFA6 rs1801311 4
22R CYP2D6 rs28371738 1
a Calculated as: # of strict discordant calls þ FFPE-T no-calls þ blood no
b Also failed due to strict discordance >5% in FFPE-T (Table 2).Filtering samples with low genotype call rate is a standard
aspect of genotyping quality control; three tumor samples
with call rate<80%were eliminated from this analysis. Retain-
ing thesesamples in theanalysiswouldhave increased therate
of tumor no-calls and discordant calls, potentially leading to
classificationof additional SNPsas FFPE-T failures.Conversely,
setting a more stringent threshold, such as call rate <90%,
would have eliminated additional samples and decreased the
amount of discordance and the number of FFPE-T SNP failures.
Similarly, adjusting the discordance thresholds above which
SNPs were classified as FFPE-T failures has a direct conse-
quence on the proportion of SNPs considered analytically vali-
dated, as depicted by the horizontal lines in Figure 2B.
The generalizability of these findings to other SNPs, tumor
types, or genotyping protocols is limited. It is not possible to
extrapolate our findings to SNPs that were not interrogated
in our system and we could not identify any genes or genetic
regions that were particularly difficult to genotype due to the
small number of individual genes represented by multiple
SNPs (data not shown). Analytic validity of our platform may
not extend to FFPE-T samples from other cancer types given
the differences in frequency of somatic genetic mutation,
rearrangement, and LOH across cancers (Cancer Genome
Atlas Network, 2012a; Cancer Genome Atlas Network, 2012b;
Cancer Genome Atlas Research Network, 2012). The SNPs





























-calls/number of patients (n ¼ 114).
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assays (Horn et al., 2010) utilized within this protocol. There-
fore, others should perform assessments of analytic validity
for genotyping their SNPs on their platform using their sam-
ples, whichmay have distinct pre-analytic features that affect
genotyping performance (Bass et al., 2014).5. Conclusions
In conclusion, genotyping from FFPE-T for breast cancer spec-
imens has slightly higher rates of no-calls but is highly concor-
dant to genotyping from germline DNA. The small loss of
genotyping performance from FFPE-T is caused primarily by
lower DNA yield, which is easily identified and overcome prior
to analysis. The success rate could likely be improved by
limiting multiplexing (Horn et al., 2010) or performing targeted
amplification prior to genotyping (Baak-Pablo et al., 2010), if
desired. While germline DNA remains the gold standard for
pharmacogenetic analyses, FFPE-T DNA is a viable alternative
for prospectiveeretrospective analyses of clinical trials. Ana-
lyses utilizing DNA isolated from FFPE should report whether
the source tissue was normal, tumor, or a mixture of the
two, and document analytic validity for genotyping each SNP
using the appropriate tissue source and genotyping platform.
We report here analytic validity for 218 cancer pharmacoge-
netics SNPs that can be accurately genotyped from breast
FFPE-T on our custom Sequenom Multiplex array.
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